We studied the efficacy of drugs indicated for mitochondrial dysfunction in the treatment of 21 patients with acute encephalopathy with onset of febrile convulsive status epilepticus at our hospital from January 2006 to December 2014. Among them, 11 patients had been treated with a mitochondrial drug cocktail consisting of vitamin B1, vitamin C, biotin, vitamin E, coenzyme Q10, and L-carnitine (prescription group) and 10 patients were not treated with the cocktail (non-prescription group). We retrospectively reviewed age, trigger, clinical form, treatment start time, and sequelae. Clinical form was classified into a biphasic group presenting acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) and a monophasic group. Sequelae were classified as (A) no sequelae group or (B) sequelae group, and differences in the interval between diagnosis and treatment were also evaluated. The sequelae were not different between the mitochondrial drug cocktail prescription and non-prescription groups, but significantly better in the group administered the mitochondrial drug cocktail within 24 h (P = 0.035). We expect that early treatment with a mitochondrial drug cocktail could prevent sequelae in acute encephalopathy with onset of febrile convulsive status epilepticus.
Introduction
Acute encephalopathy with onset of febrile convulsive status epilepticus has mainly been reported in East Asia and is classified into several subtypes according to the clinical course and neuroimaging findings. Acute encephalopathy with onset of febrile convulsive status epilepticus can be difficult to distinguish from febrile seizure status and often results in severe neurological dysfunction. In some patients with acute encephalopathy with onset of febrile convulsive status, the epilepticus shows a biphasic course, and such cases are designated as acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) [19] . AESD is clinically characterized by prolonged (N30 min) febrile seizures as the initial neurological symptom on day 1, followed by secondary seizures (most often in a cluster of complex partial seizures) associated with deterioration of consciousness level at days 4 to 6. Between the biphasic seizures, most patients present continuous disturbance of consciousness level, but some patients have normal, clear consciousness with no neurological symptoms, which may lead to an initial misdiagnosis of febrile seizure status. MRI shows no acute abnormality during the first two days, but reduced diffusion appears in the subcortical white matter during days 3 to 9 [19, 20, 22] .
One possible cause of acute encephalopathy is depletion of energy resulting from decreased mitochondrial function [11] . In mitochondrial diseases, various vitamins and coenzymes have been used clinically based on their effects on energy shortage and oxidative stress [13] , and effectiveness has been reported at high doses [12] . Therefore, this study aimed to examine the efficacy of a combination of vitamin B1, vitamin C, biotin, vitamin E), coenzyme Q10, and L-carnitine as a mitochondrial drug cocktail in the treatment of acute encephalopathy.
Methods
We defined acute encephalopathy based on criteria that have been reported as follows: (a) acute onset of severe and sustained impairment of consciousness after a preceding infection and (b) exclusion of CNS inflammation [5, 10, 15] , in addition to level of consciousness equal to or below 13 on the Glasgow Coma Scale and duration of impairment longer than 24 h, according to the diagnostic criteria of the Japanese research committee on influenza encephalopathy. Following a previous report [25] , we defined febrile convulsive status epileptics as febrile seizures longer than 30 min. We retrospectively reviewed the medical records of the patients that the attending physician diagnosed with acute encephalopathy at our hospital from January 2006 to December 2014. Then, we selected patients that met the criteria described above. The cerebrospinal fluid was examined in all cases, and CNS inflammation was excluded.
There were 23 patients with acute encephalopathy with febrile convulsive status epilepticus as an initial neurological symptom. Among them, 11 patients (Patients 1 to 11) had been treated with mitochondrial drug cocktails at our hospital since January 2009 (prescription group), after informed consent was obtained from the patient's family. For the mitochondrial drug cocktail, we used vitamin B1 (10 mg/kg), vitamin C (100 mg/kg), biotin (0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10 (5 mg/kg), and L-carnitine (30 mg/kg). In all 10 patients, the 6 drugs were administered orally, except for 2 cases: patient 3 in which only vitamin C was administered via an intravenous drip, and patient 6 in which only vitamin B1 was administered through an intravenous drip. The cocktail administration period was defined as more than 5 days and until the medical condition was stable. As an additional treatment, steroid pulse therapy was started within 24 h of encephalopathy diagnosis in all 11 cases. A single course of steroid pulse therapy consisted of 30 mg/kg/day methylprednisolone for 3 days (cases 3 and 4 received 2 courses of steroid pulse therapy). Age, trigger, clinical form, time of initial treatment, and sequelae were retrospectively reviewed using medical records. For clinical form, AESD was diagnosed by the presence of both biphasic clinical course and MRI findings of late reduced diffusion.
There were 10 patients (all 6 patients with onset prior to January 2009, and 4 patients with the onset after January 2009, for whom we have not been involved in the initial treatments) with acute encephalopathy and onset of febrile convulsive status epilepticus at our hospital who were not treated with the mitochondrial drug cocktail (non-prescription group; patients 12 to 21). All of the non-prescription patients also received steroid pulse therapy that started within 24 h of diagnosis.
Two patients of the remaining 23 patients were excluded because only part of the six cocktail drugs was administered.
Sequelae were classified as (A) no sequelae group (having no obvious functional decline in motor or intelligence function) or (B) sequelae group (all others). The family and attending physician had determined the presence or absence of sequelae at the time of hospital discharge. The sequelae (A vs. B) of the mitochondrial drug cocktail prescription and non-prescription groups were compared. In addition, the sequelae of the total 21 patients (A vs. B) based on the treatment initiation time, i.e., within 24 h and others (over 24 h and nonprescription), were analyzed.
For statistical analysis, we employed the Fisher's exact test for comparison of case history between prescription group and nonprescription group, treatment initiation time within 24 h and others, and sequelae between the mitochondrial drug cocktail prescription and non-prescription groups. Student's t-test was applied to the average age values in the prescription and non-prescription groups and treatment initiation time within 24 h and others. In all patients, blood glucose, lactate, ammonia, pH, base deficit, and anion gap levels were examined, and normal values were confirmed during the course of the study. Additionally, in the past family history of the patients, there was nothing relevant to congenital metabolic disorders, and patients with suspected congenital metabolic abnormalities were not present. There were no patients who had been administered valproic acid or anesthetics. This study was approved by the local ethics committee of Chiba Children's Hospital.
Results

Case history
The 21 cases are summarized in Tables 1, 2 . For the 11 patients in the prescription group, patient age ranged from 7 to 171 months (mean, 44.4 months), and the trigger pathogens were identified as follows: human herpes virus 6 (HHV-6) (3 cases), influenza A virus (3 cases), rotavirus (1 case), enterovirus (1 case), and unknown (3 cases). The clinical form of acute encephalopathy was AESD in 7 patients and monophasic in 4 patients. For the 10 patients in the non-prescription group, patient age ranged from 9 to 76 months (mean, 40.1 months), and the trigger pathogens were as follows: HHV-6 (3 cases), influenza A virus (1 case), rotavirus (1 case), unknown (5 cases). The clinical form of acute encephalopathy was AESD in 4 patients and monophasic in 6 patients ( Tables 1, 2 ). There was no significant difference in the case history both between prescription group and non-prescription group, and between treatment initiation time within 24 h and others (Table 2 ). In 10 cases (except for patient 8), the mitochondrial drug cocktail administration period was 5 to 23 days, with an average of 11.5 days. Patient 8 originally showed poor weight gain, and to consider the possibility of mitochondrial respiratory chain disorders, we continued the treatment for 10 months after encephalopathy until normal enzyme activity was confirmed by skin biopsy.
Sequelae
The distribution of the 21 patients was as follows: A, 11 cases; B, 10 cases. For the 11 patients in the prescription group, the distribution was as follows: A, 7 cases; B, 4 cases. The distribution for the 10 patients in the non-prescription group was as follows: A, 4 cases; B, 6 cases ( Table 3 ). The patients were further divided into a biphasic group (AESD) and a monophasic group based on the clinical form of acute encephalopathy. For the 7 patients in the prescription group with AESD, the distribution was as follows: A, 4 cases; B, 3 cases. For the 4 patients in the non-prescription group with AEDS, the distribution was as follows: A, 1 case; B, 3 cases (Table 4) . For the 3 patients in the prescription group with monophasic acute encephalopathy, the distribution was as follows: A, 2 cases; B, 1 case. For the 6 patients in the non-prescription group with monophasic acute encephalopathy, the distribution was as follows: A, 3 cases; B, 3 cases (Table 5) .
There was no significant difference in the distribution of the severity of sequelae (A vs B) between the mitochondrial drug cocktail prescription and non-prescription groups in the total 21 patients and in both AESD and monophasic groups (Tables 3, 4, 5).
Importance of the time of treatment initiation
Finally, the total 21 patients' sequelae were compared based on the mitochondrial drug cocktail treatment initiation time: within 24 h and others (over 24 h or non-prescription). The sequelae of the 5 patients treated within 24 h of diagnosis were as follows: A, 5 cases; B, 0 cases. The sequelae of the 16 patients (treated over 24 h or nonprescription) were as follows: A, 10 cases; B, 11 cases. Sequelae were significantly better in the group administered the drug cocktail within 24 h (P = 0.035) ( Table 6 ).
Discussion
We studied the efficacy of a mitochondrial drug cocktail in the treatment of acute encephalopathy with onset of febrile convulsive status epilepticus. The most important finding in this study was that sequelae were significantly better in the group administered mitochondrial drug cocktail within 24 h.
The mechanism of acute encephalopathy with onset of febrile convulsive status epilepticus has not been sufficiently elucidated, and the condition is often classified into subtypes such as AESD, acute necrotizing encephalopathy (ANE), and other monophasic types in Japan [11, 24] . Excitotoxic injury with delayed neuronal death has been hypothesized as a possible mechanism of AESD, based on MR spectroscopic findings [11, 20] and cytokine analysis of cerebrospinal fluid [7] .
Acute encephalopathy is more common in East Asia than in Europe or North America, indicating that genetic factors play an important role [2, 11] . Carnitine palmitoyl transferase II (CPTII) polymorphisms [2, 17] , SCN1A mutations [14] , and adenosine A2A receptor polymorphisms [16] have recently been reported as predisposing factors for the onset of acute encephalopathy. Among them, CPTII is the most likely etiological candidate for encephalopathy. A thermolabile CPTII phenotype and a CPTII polymorphism in Japanese patients with multiple types of acute encephalopathy have been reported [2, 17] . Given that CPTII is an enzyme localized on the mitochondrial inner membrane that removes fatty acids from carnitine, CPTII deficiency leads to mitochondrial dysfunction and a lack of energy in the wake of severe infections [1, 6, 17, 23] . Although further studies should target the relationship between CPTII polymorphism and treatment efficacy, the demonstrated involvement of mitochondrial dysfunction in acute encephalopathy suggests that mitochondrial drug cocktails should be explored for the treatment of acute encephalopathy [3] .
There are no established treatments for mitochondrial dysfunction, but various vitamins and coenzymes have been clinically used based on their effects on energy shortage and oxidative stress [13] , and effectiveness at high dose has already been reported [12] . Therefore, we employed vitamin B1 (10 mg/kg), vitamin C (100 mg/kg), biotin (0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10 (5 mg/kg), and Lcarnitine (30 mg/kg) as a mitochondrial drug cocktail based on previous reports [4, 9, 12, 13, 21] . We started prescribing mitochondrial drug cocktails to patients with acute encephalopathy approximately 6 years ago after obtaining informed consent. Although the dose of the mitochondrial drug cocktail was consistent and administration was subject to a unified protocol, the time from diagnosis to the start of prescription differed among the cases because their physicians determined their applications independently.
In this study design, there was no significant difference in the average age of the patients in the prescription and non-prescription groups. Although no significant relationship has been reported between the trigger pathogen and the type of encephalopathy [11, 17] , we found that HHV6 was the most common pathogen, followed by the influenza virus; this finding is in agreement with those of previous reports [8, 18] . There was no significant difference in prognosis (A vs B) between the mitochondrial drug cocktail prescription and non-prescription groups among the 21 patients and in both AESD and monophasic groups, probably because of the small number of patients and the delay in starting the mitochondrial drug cocktail after the diagnosis of encephalopathy. However, no sequelae were observed in the 5 cases in which mitochondrial drug cocktail administration was initiated within 24 h of encephalopathy diagnosis. Given that the outcome was significantly better in the group administered the mitochondrial drug cocktails within 24 h, we consider that early administration within 24 h of diagnosis may provide a prophylactic effect.
Although there are reports of various vitamins and coenzymes as treatments for mitochondrial diseases [4, 9, 12, 13, 21] and a report of the combination of creatine monohydrate, coenzyme Q10, and alphalipoic acid as a "mitochondrial cocktail" for mitochondrial cytopathies [4] , there are no reports in which a combination of various vitamins and coenzymes was administered for acute encephalopathy. Considering the mechanisms of these constituents, it is likely that the mitochondrial drug cocktail used in this study provides an effective treatment for acute encephalopathy. Moreover, there have been no obvious side effects in our patients, and administration of the drug cocktail was relatively easy.
The limitations of our study stem from retrospective analysis and the small number of patient, further prospective study in larger cohorts is necessary to conclude the observations; however, we consider that speedy administration of mitochondrial drug cocktails is worthwhile in cases of acute encephalopathy and in individuals with a high risk of encephalopathy (such as those with status epilepticus or spasm of the cluster associated with fever) because of the potential to prevent the development of sequelae or the onset of acute encephalopathy.
